New York, NY – Kapitus, a leading provider of financing to small and medium-sized businesses, has received rating affirmation from Kroll Bond Rating Agency (“KBRA”) on three classes of notes it issued through SFS Asset Securitization LLC (“SFS”).

According to KBRA, “the affirmations are due to KBRA’s analysis of the supporting collateral pool of receivables, Kapitus’s managed static pool performance data and current credit enhancement levels for each class of notes.” In addition, the ratings on the three classes of notes have been removed from “Watch Downgrade”. On March 30, 2020 KBRA placed all outstanding ratings from 10 U.S. small business ABS transactions, covering 29 securities and $2.1 billion outstanding, on Watch Downgrade owing to the economic effects of Covid-19.

“We are pleased with the rating affirmations from KBRA as it underscores our approach to underwriting and credit risk and shows the importance of proactive management through the ongoing covid-19 pandemic,” said Andrew Reiser, Chief Executive Officer at Kapitus. “We are proud of the fact that Kapitus is among the only companies in the space to perform through this crisis and remain fully open for business, and given the current consolidation of the industry we believe we are well positioned for future growth.”

ABOUT KAPITUS
Founded in 2006 and headquartered in NYC, Kapitus is one of the most reliable and respected names in small business financing. As both a direct lender and a marketplace built with a trusted network of lending partners, Kapitus is able to provide small businesses the financing they need, when and how it is needed. With one application business owners can save time and money, while eliminating the stress that comes with applying to different lenders. At Kapitus, we believe that business owners should be able to focus on running their business, while we take care of the financing. To learn more, visit www.kapitus.com.

The notes are not registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from, or a transaction not subject to, registration requirements. The notes were offered only to qualified institutional buyers under Rule 144A and to persons outside the United States pursuant to Regulation S under the Securities Act. This press release shall not constitute an offer to sell, or the solicitation of an offer to sell the notes, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which, or to any person to whom, such an offer or solicitation or sale is unlawful.

Strategic Funding Source Announces Launch of New Brand Identity; Unites its Funding Arm and Servicing Arm Under the name Kapitus

Change reflects new strategy, expansion of product portfolio, technology advancements and a renewed commitment to provide financing to more businesses

New York, NY – January 15, 2019 – Strategic Funding Source, a veteran of the small and medium-sized business alternative lending space, today announced the launch of a new corporate brand identity, including a new name. As part of this rebrand, the funding division and servicing division will be united under the name Kapitus. The unification of these two divisions will allow for an improved experience for both clients and partners.

Since its inception in 2006, Strategic Funding Source has provided over $2 billion to almost 40,000 businesses in hundreds of industries across the U.S. Over the past two years, the organization has been proactively building out its executive team, bringing in a wealth of experience to transform its risk model, underwriting processes, lending capacity and product line, technology capabilities and customer experience.

With these and other planned advancements, the company required a new brand that better reflected the company’s commitment to be a reliable source of capital to all small and mid-sized business owners.

“The small business lending landscape is consolidating around a few strong and reputable companies. Over the last several years, Kapitus has experienced tremendous growth both in its product offerings to small and medium-sized businesses and in the total number of businesses it serves” said Andy Reiser, CEO of Kapitus. “We chose a name and identity that represents our strength and stability as well as our promise to be a responsible and fair source of capital to small and medium-sized businesses nationwide.”

Along with the name change there will be a new logo, tagline (“Let’s Grow Together”) and domain name (kapitus.com). The rebrand is the first step in the company’s strategy to grow its own financing product line, add to its marketplace of 3rd party lenders and create a foundation for new partnership opportunities. The new brand also represents the company’s commitment to keep the human touch throughout the financing process, while improving customer experience through technology to aid the decisioning process and improve speed to funding.

“This is an exciting change for us,” added Reiser. “This new branding builds upon our history and pays allegiance to our standing as a leader in a fast-evolving industry, opening the door for future opportunities for us, our clients and our partners.”

About Kapitus
Founded in 2006 and headquartered in NYC, Kapitus is one of the most reliable and respected names in small business financing. As both a direct lender and a marketplace built with a trusted network of lending partners, Kapitus is able to provide small businesses the financing they need, when and how it is needed. With one application business owners can save time and money, while eliminating the stress that comes with applying to different lenders. At Kapitus, we believe that business owners should be able to focus on running their business, while we take care of the financing. To learn more, visit www.kapitus.com.

NEW YORK, NY– Strategic Funding, a leading provider of alternative financing to small and midsize businesses, today announced the expansion of its executive team with the appointment of a new Chief Financial Officer and the addition of two key roles to the team. Anthony Rose has assumed the role of Chief Financial Officer; Jeffrey Newman joins the team as the company’s Chief Risk Officer; and Arun Narayan has been promoted to take on the new role of Chief Product Officer.
Rose, who developed strategic and financial initiatives at JPMorgan Chase, Credit Suisse and most recently, Dime Community Bancshares, brings over 15 years of leadership experience in the finance industry. In this new role, Rose will be responsible for charting the financial direction of Strategic Funding, while serving as the company’s strategic and tactical financial expert.
Newman, most recently Chief Credit Officer at Citibank’s US Retail Bank for Consumer and Small Business lending, will be leveraging over 25 years of experience to refine and enhance Strategic Funding’s credit, risk, and fraud management models. In addition, he will play a key role in managing the organization’s portfolio to ensure that the company meets its profitability goals.
Narayan, who has been with Strategic Funding since 2014, will be taking on the newly created role of Chief Product Officer to deliver the company’s next phase of growth through innovation across product development and management.
“We are excited to welcome our new executive team members,” said Andrew Reiser, CEO of Strategic Funding. “With the addition of these leaders we are confident that we now have the right team to transform our organization and bring Strategic Funding to its next level of growth.”

ABOUT STRATEGIC FUNDING

Founded in 2006 and headquartered in NYC, Strategic Funding has been recognized by customers and the industry as one of the most reliable and respected names in small business financing. With flexible financing options, we provide small businesses with the working capital they need to take advantage of opportunities and grow. To learn more, visit www.sfscapital.com

NEW YORK, NY– Strategic Funding announced today the launch of Helix, a financing product created to provide easy and fast funding to independent healthcare practices. Different from other alternative types of financing, Helix makes larger funding amounts and longer terms available to healthcare professionals. Funding amounts range from $10,000 – $500,000 and terms go out as far as 36 months. In addition, the Helix product comes with a risk matrix built specifically for healthcare businesses allowing for more customized financing options and quicker approvals.
As a part of this launch, Strategic Funding has partnered with Bankers Healthcare Group (BHG), a leader in the healthcare financing industry since 2001. Through this partnership, Strategic Funding and BHG will be able to offer an expanded set of financing products to their customers, and extend new options to practices that have seen little to no alternative financing options in the past.
“Over the past few years, we have seen independent healthcare and medical practices struggle due to lower insurance reimbursements and longer wait times for insurance payouts. The combination of these two situations has made it difficult for many practices to consistently maintain a cash flow. This lack of working capital has resulted in disrupted operation and, in too many cases, practices needing to close or be sold to larger institutions,” said Andrew Reiser, CEO of Strategic Funding.
“We knew we wanted to create a product specifically tailored to meet the needs of the health care industry. Which is why we partnered with BHG. Leveraging their years of experience in the healthcare financing industry, we have created a product that makes sense for these practices,” adds Reiser.
“We are thrilled to be partnering with Strategic,” said Bob Castro, President and Co-founder of BHG. “Through this partnership we’re able to expand financing options available for these practices. Healthcare professionals require financing built to work with the unique business challenges they face. This partnership allows us to do that. We can now offer financing for terms that have not been readily available in the past. It’s a win-win for all involved.”

To learn more about Helix visit: https://kapitus.com/products-services/helix-healthcare-financing/

ABOUT STRATEGIC FUNDING

Founded in 2006 and headquartered in NYC, Strategic Funding has been recognized by customers and the industry as one of the most reliable and respected names in small business financing. Since its inception, Strategic Funding has provided nearly $1.5 billion to small business owners across the country. With flexible financing options, the company provides small businesses with the working capital they need to take advantage of opportunities and grow. To learn more, visit www.sfscapital.com

ABOUT BANKERS HEALTHCARE GROUP

Bankers Healthcare Group provides innovative, hassle-free financial solutions exclusively to healthcare professionals. Since 2001, BHG has funded more than $3 billion to satisfied customers nationwide and worked with more than 110,000 practitioners. BHG is proud to maintain partnerships with leading healthcare industry associations, and is continually recognized for innovation, continued growth and being a best place to work. BHG is partially owned by Pinnacle Financial Partners (PNFP). To learn more, visit www.bankershealthcaregroup.com, and follow us on Twitter, LinkedIn and Facebook.

NEW YORK, NY– Strategic Funding announced today that the Foundation Fighting Blindness (FFB), has been designated as one of the two official charities it will be supporting in 2017 through its corporate and social responsibility programs. As part of its national sponsorship of this non-profit organization, Strategic Funding has agreed to work with its community of employees, partners and clients to raise funds for this cause throughout the duration of 2017. Strategic Funding will match the first $20,000 in donations made.

FFB has made it its mission to drive the research that will provide preventions, treatments and cures for the over 10 million Americans affected by the entire spectrum of retinal degenerative diseases. American’s like Kelly who has been living with Stargardt disease for almost 8 years. Stargardt disease is an inherited disorder of the retina and is caused by the death of photoreceptor cells in the macula. While it is the most common form of inherited macular degeneration, there are no known treatments for Stargardt.

“We are excited to name the Foundation Fighting Blindness as an official charity in our 2017 corporate giving program,” said Andrew Reiser, CEO of Strategic Funding. “With a close family friend who is affected by retinal disease, I have seen first-hand the amazing work that the FFB has done for her. The entire Strategic Funding team is excited to be sponsoring such a worthy cause.”

Since its inception in 1971, the Foundation Fighting Blindness has raised more than $700 million for retinal disease research. With these funds, it has funded 134 research studies, identified over 250 retinal degeneration causing genes, and has supported clinical trials that, in some cases, have resulted in significant vision improvement for trial participants.

ABOUT STRATEGIC FUNDING

Founded in 2006 and headquartered in NYC, Strategic Funding has been recognized by customers and the industry as one of the most reliable and respected names in small business financing. With flexible financing options, we provide small businesses with the working capital they need to take advantage of opportunities and grow. To learn more, visit www.sfscapital.com

ABOUT FOUNDATION FIGHTING BLINDNESS

Since the Foundation Fighting Blindness was established in 1971 it has raised more than $700 million for research on preventing, treating and curing blindness caused by inherited retinal diseases. In excess of 10 million Americans, and millions more worldwide, experience vision loss due to retinal degenerations. Through its support of focused and innovative science, and by teaming with industry, the Foundation drives the research that has and will continue to provide treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and other inherited retinal diseases. Our goal is to advance the most promising retinal disease research in the world and across the spectrum of retinal degenerative diseases. You can help. Every donation moves us closer to a cure.